Why the study?
Does antisense oligonucleotide inhibition of apolipoprotein C-III reduce plasma apoC-III and triglycerides in preclinical models and healthy subjects?
Population
Preclinical models (rodents, nonhuman primates) and healthy subjects in a phase I clinical trial
Design
Preclinical
Authors
Loading...
Supports further development for hypertriglyceridemia; leaves open clinical translation from animal models.
Does antisense oligonucleotide inhibition of apolipoprotein C-III reduce plasma apoC-III and triglycerides in preclinical models and healthy subjects?
Antisense inhibition of apoC-III effectively reduces plasma triglycerides and apoC-III, supporting further clinical investigation for hypertriglyceridemia.
Graham et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: